HINOVA PHARMACEUTICALS INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.5 CNY | +0.88% |
|
-12.40% | -49.11% |
| Apr. 26 | Hinova Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 08 | China Stocks Fall Ahead of March Economic Data Release | MT |
| Sales 2024 * | 130M 17.94M | Sales 2025 * | 487M 67.2M | Capitalization | 2.62B 362M |
|---|---|---|---|---|---|
| Net income 2024 * | -472M -65.13M | Net income 2025 * | -124M -17.11M | EV / Sales 2024 * | 20.2 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 5.39 x |
| P/E ratio 2024 * |
-5.56
x | P/E ratio 2025 * |
-21.3
x | Employees | 181 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 59.28% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.88% | ||
| 1 week | -12.40% | ||
| Current month | -12.40% | ||
| 1 month | -11.43% | ||
| 3 months | -20.47% | ||
| 6 months | -49.54% | ||
| Current year | -49.11% |
1 week
25.60
29.95
1 month
25.6031.65
Current year
23.9653.28
1 year
23.9658.99
3 years
23.9678.77
5 years
23.9678.77
10 years
23.9678.77
| Managers | Title | Age | Since |
|---|---|---|---|
Xing Hai Li
FOU | Founder | 61 | 13-02-04 |
Yuan Wei Chen
CEO | Chief Executive Officer | 61 | 13-02-04 |
Ze Yan Shi
DFI | Director of Finance/CFO | 43 | 21-11-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yuan Wei Chen
CEO | Chief Executive Officer | 61 | 13-02-04 |
Xing Hai Li
FOU | Founder | 61 | 13-02-04 |
Yuan Lun Chen
BRD | Director/Board Member | 54 | 20-09-20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 26.5 | +0.88% | 647,553 |
| 24-06-06 | 26.27 | -7.76% | 1,196,214 |
| 24-06-05 | 28.48 | -2.83% | 421,879 |
| 24-06-04 | 29.31 | -0.85% | 614,139 |
| 24-06-03 | 29.56 | -2.28% | 781,488 |
End-of-day quote Shanghai S.E., June 06, 2024
More quotes
Hinova Pharmaceuticals Inc is a Chinese company mainly engaged in the research and development of innovative drugs for critical illnesses. The Company focuses its research on the fields of tumor, metabolic diseases and other critical illnesses. The Company's research platforms include a deuterated drug development platform, a Proteolysis-targeting chimera (PROTAC) technology platform, a targeted drug discovery and validation platform, and a lead compound optimization screening platform. The Company has diversified product portfolios, which are in various clinical test phases, including HC-1119 for prostate cancer, HP501 for hyperuricemia, and HP558 for cancer of the esophagus, among others. The Company conducts clinical tests in domestic and overseas areas.
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
26.5
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -49.11% | 362M | |
| +51.85% | 57.87B | |
| +41.42% | 40.25B | |
| -5.25% | 39.94B | |
| -5.16% | 28.54B | |
| +12.79% | 26.4B | |
| -20.18% | 19.33B | |
| +30.88% | 12.4B | |
| +0.61% | 12.23B | |
| +25.06% | 12.2B |
- Stock Market
- Equities
- 688302 Stock
